Emerging from stealth mode, Aardvark rounds up enough cash to put its lead drug through Prader-Willi PhII

Josh Sullivan

When Aardvark Therapeutics CEO Tien Lee started his work on the biotech’s lead candidate, appetite suppression was the goal for the small molecule. Soon after …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Emerging from stealth mode, Aardvark rounds up enough cash to put its lead drug through Prader-Willi PhII

Josh Sullivan

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Emerg­ing from stealth mode, Aard­vark rounds up enough cash to put its lead drug through Prad­er-Willi PhII

Sign up to read this article for free.

more like this

Celldex Therapeutics

Hampton, NJ, USA

Emerging from stealth mode, Aardvark rounds up enough cash to put its lead drug through Prader-Willi PhII